FDA Panel Narrowly Favors Expanding Patient Population For Biventricular Pacing
Executive Summary
With the help of a tie-breaker vote, the Circulatory System Devices Advisory Panel said the benefits outweigh the risks of expanding the indications for biventricular cardiac resynchronization therapy devices to include patients at risk for developing new or worsened heart failure because of their need for right ventricular pacing. Medtronic is seeking the expansion in a submission before FDA.
You may also be interested in...
American Heart Association In Brief
Study results on ICD programming, biventricular pacing and more from the 2012 AHA Scientific Sessions in Los Angeles.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.